NIKKEI 225
38,202.37 -632.73 (-1.63%) HANG SENG
18,313.86 -165.51 (-0.90%) CRUDE OIL
78.69 +0.31 (+0.40%) GOLD FUTURES
2,322.20 -2.00 (-0.09%) DOW
38,959.09 +74.83 (+0.19%) Bitcoin GBP
50,085.23 -663.89 (-1.31%)
GLPG May 2024 32.500 call
| Previous close | 0.3000 |
| Open | 0.3000 |
| Bid | 0.0000 |
| Ask | 1.0000 |
| Strike | 32.50 |
| Expiry date | 2024-05-17 |
| Day's range | 0.3000 - 0.3000 |
| Contract range | N/A |
| Volume | |
| Open interest | 16 |
Insider MonkeyGalapagos NV (NASDAQ:GLPG) Q1 2024 Earnings Call Transcript
Galapagos NV (NASDAQ:GLPG) Q1 2024 Earnings Call Transcript May 4, 2024 Galapagos NV isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Sofie Van Gijsel: Welcome all to the audio webcast of Galapagos’ Q1 2024 Results. I’m Sofie Van Gijsel, Investor Relations […]
Simply Wall St.Galapagos First Quarter 2024 Earnings: EPS: €0.36 (vs €0.35 in 1Q 2023)
Galapagos ( AMS:GLPG ) First Quarter 2024 Results Key Financial Results Revenue: €62.4m (down 65% from 1Q 2023). Net...
Globe NewswireGalapagos reports first quarter 2024 financial results
Advanced potentially best-in-class cell therapy and small molecule R&D pipeline comprising four clinical assets and >15 discovery programs in oncology and immunologyExecuted agreements with BridGene Biosciences and Thermo Fisher Scientific, and investment in Frontier MedicinesTransferred Jyseleca® business to Alfasigma S.p.A., freeing up resources to invest in growth areasGroup net revenues in the first quarter of €100 millionCash and current financial investments of €3.6 billion on 31 March 202
